secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001628280-22-029065
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel Q3 revenue $38.6M (+12% YoY); MACI $31M (+30%); net loss $6.6M; FY22 guidance $164-166M
--------------------------------------------------------------------------------

- Total net revenue $38.6M (+12% YoY); MACI net revenue $31.0M (+30% YoY); Epicel $7.3M; NexoBrid $0.2M.
- Net loss of $6.6M ($0.14 per share) vs $4.9M loss in Q3 2021; adjusted EBITDA $3.3M.
- Full-year 2022 guidance: total revenue $164-166M, MACI $130-132M, burn care ~$34M, gross margin mid-60%.
- Cash and investments $133M, no debt; ninth straight quarter of positive adjusted EBITDA and operating cash flow.
- NexoBrid BLA review progressing with FDA inspections; Type C meeting scheduled for MACI arthroscopic delivery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000162828022029065/0001628280-22-029065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000162828022029065/vcel-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-029065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer